Immunic appoints Nash as CEO of Gliomic subsidiary; updates Vitt's employment terms

IMMUNIC, INC.

Duane Nash to serve as CEO and President of wholly-owned Gliomic Therapeutics effective Jan 1, 2026, with monthly salary of $33,987.
Daniel Vitt enters new employment agreement: $305,000 annual salary, 55% target bonus, 50% US working time, $50,000 housing reimbursement.
Vitt's Suspension Agreement with Immunic AG terminated; he will now devote 50% time to Immunic AG with €282,826.50 annual salary and variable remuneration.
Nash's prior Executive Chairman agreement expired Dec 31, 2025; he remains Board Chairman but receives no cash retainer during his Gliomic employment term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.